enGene Holdings Inc

ENGN30 Nov 2024
Healthcare
$8.6
+0.00 (+0.46%)
Lowest Today
$8.56
Highest Today
$8.7
Today’s Open
$8.6
Prev. Close
$8.61
52 Week High
$18.4
52 Week Low
$4.42
To Invest in enGene Holdings Inc

enGene Holdings Inc

Healthcare
ENGN30 Nov 2024
+0.00 (+0.46%)
1M
3M
6M
1Y
5Y
Low
$8.56
Day’s Range
High
$8.7
8.56
52 Week Low
$4.42
52-Week Range
52 Week High
$18.4
4.42
1 Day
-
1 Week
+4.34%
1 month return
-0.57%
3 month return
+23.92%
6 month return
-17.61%
1 Year return
+10.61%
3 Years return
-
5 Years return
-
10 Years return
-

Market Status

Fundamentals
Market Cap
438.91 mln
PB Ratio
1.91
PE Ratio
0
Enterprise Value
206.09 mln
Total Assets
86.96 mln
Volume

Company Financials

Fund house & investment objective

Company Information
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Organisation
enGene Holdings Inc
Employees
31
Industry
Biotechnology
CEO
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step